Bhawna Dev MD, Presenter: Nothing to Disclose

Sameera Gaddam MBBS, Abstract Co-Author: Nothing to Disclose

To determine the efficacy of MRgFUS ablation in organ-preserving treatment of adenomyosis.

We describe a small group of 14 patients (median age 31 years-old, range 36-44), treated for adenomyosis and followed up for six months. For each patient we had collected the Symptom Severity Score (SSS) as well as the Visual Analog Scale (VAS) and the number of reported pads replaced by the patient.

: The SSS had significantly decreased from a median of 56 (range 19 to 65) to 16 (range 0 to 34), by the six months follow-up visit. In addition, the VAS had decreased from a median of 7 (range 5 to 8) prior to treatment to 2 (range 2 to 6). Finally, the number of pads had decreased from a median of 7 (range 4 to 9) to 4 (range 3 to 5) six months post treatment. No adverse events were observed during the treatments or the follow-up period.

MRgFUS can significantly increase the quality of life for patients suffering from adenomyosis. Symptom relief is also accompanied by a reduction in pain and a lessening of the associated bleeding during the menstrual period.

MR guided focused ultrasound surgery ( MRgFUS ) is a newer organ preserving treatment option in Adenomyosis and is a good option for patients wanting to preserve their uterus.

Dev, B, Gaddam, S, Novel Organ Preserving Treatment Option—MR Guided Focused Ultrasound Surgery (MRgFUS) in Adenomyosis: Initial Forebode Results.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14012217.html